Business
Actuate is a clinical-stage biopharmaceutical company developing elraglusib, a GSK-3 beta inhibitor for difficult-to-treat cancers.
Actuate improved losses and equity, but its elraglusib program still carries a going-concern warning.
The read at a glance✓ Audited against SEC data
- Business mix — Elraglusib GSK-3 beta inhibitorNote
- Revenue — No revenue in local bundleNote
- Profitability — Net loss improved to $22.2MOK
- Cash burn — Cash from operations improved to -$19.2MOK
- Balance sheet — Equity rose to $7.9MOK
- Insiders — 0 buys / 1 sellWatch
- Accounting — Going-concern warningWatch
Leadership changes
From ACTUATE THERAPEUTICS, INC.'s own filings, the day they're filed.
- Jason Keyes · director · appointmenteff. 2024-08-12
- Roger Sawhney · director · appointmenteff. 2024-08-12
- Amy Ronneberg · director · appointmenteff. 2024-08-12
Latest filings
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-07-17
- 8-K · Company announcement2026-05-22
- 10-Q · Quarterly report2026-05-14
- 8-K · Company announcement2026-05-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ACTUATE THERAPEUTICS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.